Who we are
At Soteria Biotherapeutics, we are developing a next generation of bispeciﬁc T-cell engagers to treat patients with solid tumor cancers. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispeciﬁc antibody therapies, enabling safer and more eﬃcacious treatments through pulsatile activity, reduced side eﬀects and higher dosing. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives.
The company was founded in 2018 by Jim Wells, PhD, renowned protein engineer and professor at UC San Francisco, Zachary Hill, PhD, and Alexander Martinko, PhD. The company has exclusively licensed technology from UC San Francisco based on the work of Drs. Wells, Hill and Martinko.